<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Abstract The COVID-19Â pandemic caused by the newly emerged severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) puts the world in an"/>
 <result pre="The COVID-19Â pandemic caused by the newly emerged severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented"/>
 <result pre="COVID-19Â pandemic caused by the newly emerged severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented crisis,"/>
 <result pre="remdesivir SARS-CoV-2 page-count: Based on the previous emergence of severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
 <result pre="SARS-CoV-2 page-count: Based on the previous emergence of severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
 <result pre="page-count: Based on the previous emergence of severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV),"/>
 <result pre="of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), it was expected that the globe"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), it was expected that the globe would"/>
 <result pre="a new strain from the CoV family, known as severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan/China causingÂ COVID-19."/>
 <result pre="new strain from the CoV family, known as severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan/China causingÂ COVID-19. On"/>
 <result pre="strain from the CoV family, known as severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2), emerged in Wuhan/China causingÂ COVID-19. On March"/>
 <result pre="CoVs and host cells. Nanoparticles (NPs), which are studded with" exact="viral" post="antigens or antibodies, could be used against SARS-CoV-2 and"/>
 <result pre="around 79.5% sequence identity with SARS-CoV [14]. Two-thirds of the" exact="viral" post="genome (ORF1a/b) translate to two polyproteins, pp1a and pp1ab,"/>
 <result pre="human cells and rapid infection, specifically in cells of the" exact="lower" post="respiratory system that express high levels of ACE2 receptors"/>
 <result pre="cells and rapid infection, specifically in cells of the lower" exact="respiratory" post="system that express high levels of ACE2 receptors [21â€&quot;24]."/>
 <result pre="with the host cell receptors, it enters and releases its" exact="viral" post="genome to start RNA synthesis using RNA-dependent RNA polymerase"/>
 <result pre="Envelope; HE: Hemagglutinin; N: Nucleocapsid; M: Membrane; S: Spike; SARS-CoV-2:" exact="Severe" post="acute respiratory syndrome coronavirus-2. (B) Reproduced with permission from"/>
 <result pre="HE: Hemagglutinin; N: Nucleocapsid; M: Membrane; S: Spike; SARS-CoV-2: Severe" exact="acute" post="respiratory syndrome coronavirus-2. (B) Reproduced with permission from [13]."/>
 <result pre="Hemagglutinin; N: Nucleocapsid; M: Membrane; S: Spike; SARS-CoV-2: Severe acute" exact="respiratory" post="syndrome coronavirus-2. (B) Reproduced with permission from [13]. Types"/>
 <result pre="N: Nucleocapsid; M: Membrane; S: Spike; SARS-CoV-2: Severe acute respiratory" exact="syndrome" post="coronavirus-2. (B) Reproduced with permission from [13]. Types of"/>
 <result pre="December 2019 in Wuhan (China). It infects human, causing COVID-19" exact="disease" post="and is currently is responsible for the worldwide health"/>
 <result pre="natural host of the virus, however, it might have an" exact="intermediate" post="host [34â€&quot;36]. The clinical spectrum of COVID-19 varies from"/>
 <result pre="COVID-19 varies from no symptoms to multiorgan failure such as" exact="respiratory" post="failure. The common symptoms include fever, cough, fatigue, dyspnea,"/>
 <result pre="loss of taste or smell [37]. Gastrointestinal symptoms such as" exact="diarrhea" post="can also be a presenting feature for COVID-19. This"/>
 <result pre="a connection between gut functionality and microbiome responses to SARS-CoV-2" exact="infection" post="[38]. Alterations of fecal microbiota are considered to be"/>
 <result pre="SARS-CoV-2 fecal levels and COVID-19 severity [39]. While SARS-CoV-2 has" exact="lower" post="mortality rate than SARS-CoV and MERS-CoV, the number of"/>
 <result pre="show positive results even after individuals show negative results in" exact="respiratory" post="samples [44]. Therapeutic approaches Due to a lack of"/>
 <result pre="CoV family. Understanding the coronaviral genome and the processes of" exact="viral" post="replication and pathogenesis will enable researchers to develop specific"/>
 <result pre="antigens such as live-attenuated virus [45â€&quot;47], inactivated virus or recombinant" exact="viral" post="parts (DNA, mRNA and proteins) or through exposing the"/>
 <result pre="protein CoVs including SARS-CoV-2 Simplicity, stability and rapid productionSafety (no" exact="infectious" post="virus) [53,56,60,62] RNA vaccines SARS-CoV-2 spike protein SARS-CoV-2 SimplicitySafety"/>
 <result pre="virus) [53,56,60,62] RNA vaccines SARS-CoV-2 spike protein SARS-CoV-2 SimplicitySafety (no" exact="infectious" post="virus) [64,65] Recombinant protein vaccines Spike proteinNucleocapsid proteinMembrane protein"/>
 <result pre="vaccines Spike proteinNucleocapsid proteinMembrane protein CoVs including SARS-CoV-2 Safety (no" exact="infectious" post="virus)Stimulate the immune response and release antibodiesAdjuvants needed to"/>
 <result pre="release antibodiesAdjuvants needed to increase immunogenicity [80â€&quot;83,85,87] CoV: Coronavirus; SARS-CoV:" exact="Severe" post="acute respiratory syndrome coronavirus. Multiple antigenic components using the"/>
 <result pre="antibodiesAdjuvants needed to increase immunogenicity [80â€&quot;83,85,87] CoV: Coronavirus; SARS-CoV: Severe" exact="acute" post="respiratory syndrome coronavirus. Multiple antigenic components using the whole"/>
 <result pre="needed to increase immunogenicity [80â€&quot;83,85,87] CoV: Coronavirus; SARS-CoV: Severe acute" exact="respiratory" post="syndrome coronavirus. Multiple antigenic components using the whole virus"/>
 <result pre="to increase immunogenicity [80â€&quot;83,85,87] CoV: Coronavirus; SARS-CoV: Severe acute respiratory" exact="syndrome" post="coronavirus. Multiple antigenic components using the whole virus either"/>
 <result pre="immunogenicity [80â€&quot;83,85,87] CoV: Coronavirus; SARS-CoV: Severe acute respiratory syndrome coronavirus." exact="Multiple" post="antigenic components using the whole virus either as live-attenuated"/>
 <result pre="the potential risk of reversion to virulent phenotype due to" exact="residual" post="infectivity. Thereby, safety and stability of these vaccines are"/>
 <result pre="mechanisms needs to be performed to develop safe vaccines [46,47,49]." exact="Combined" post="NSP16 and 2â€²O MTase) broad attenuation showed a promising"/>
 <result pre="avoiding risk of reversion [46]. Furthermore, Graham et al. produced" exact="stable" post="live-attenuated SARS-CoV vaccine with an optimum balance between virulence"/>
 <result pre="double inactivation of the virus is a successful approach, preventing" exact="viral" post="reversion and pathogenesis. A SARS-CoV vaccine, which was prepared"/>
 <result pre="virus replication in the host cells without the risk of" exact="infection" post="[49]. Recently, Sinovac Biotech developed a purified inactivated vaccine"/>
 <result pre="[50]. Figure 2. Clinical phase vaccine candidates for the coronavirus" exact="disease" post="2019. aAPC: Artificial antigen-presenting cells; Ad5-nCoV: Adenovirus Type 5"/>
 <result pre="the coronavirus disease 2019. aAPC: Artificial antigen-presenting cells; Ad5-nCoV: Adenovirus" exact="Type 5" post="vectored COVID-19 vaccine; DC: Dendritic cell; LNP: Lipid nanoparticles;"/>
 <result pre="antigen-presenting cells; Ad5-nCoV: Adenovirus Type 5 vectored COVID-19 vaccine; DC:" exact="Dendritic cell;" post="LNP: Lipid nanoparticles; LV: Lentiviral vector; S: Spike; SARS-CoV-2:"/>
 <result pre="cell; LNP: Lipid nanoparticles; LV: Lentiviral vector; S: Spike; SARS-CoV-2:" exact="Severe" post="acute respiratory syndrome coronavirus-2. DNA vaccines DNA vaccine platforms,"/>
 <result pre="LNP: Lipid nanoparticles; LV: Lentiviral vector; S: Spike; SARS-CoV-2: Severe" exact="acute" post="respiratory syndrome coronavirus-2. DNA vaccines DNA vaccine platforms, which"/>
 <result pre="Lipid nanoparticles; LV: Lentiviral vector; S: Spike; SARS-CoV-2: Severe acute" exact="respiratory" post="syndrome coronavirus-2. DNA vaccines DNA vaccine platforms, which are"/>
 <result pre="nanoparticles; LV: Lentiviral vector; S: Spike; SARS-CoV-2: Severe acute respiratory" exact="syndrome" post="coronavirus-2. DNA vaccines DNA vaccine platforms, which are developed"/>
 <result pre="DNA vaccines DNA vaccine platforms, which are developed using plasmid-encoding" exact="viral" post="antigens, could produce cellular and humoral immunity (for reviews,"/>
 <result pre="that are released in response to vaccines help in the" exact="viral" post="entry to host cells, thereby increasing incidence of infection"/>
 <result pre="the viral entry to host cells, thereby increasing incidence of" exact="infection" post="[53,56,58]. Additionally, protective effects are obtained with N-specific CD8+"/>
 <result pre="and a polyprotein protease, using lentiviral vectors (LVs) to express" exact="viral" post="proteins and immune modulatory genes. In case of LV-SMENP-DC"/>
 <result pre="and immune modulatory genes. In case of LV-SMENP-DC vaccine, these" exact="viral" post="proteins and immune modulatory genes are able to modify"/>
 <result pre="vaccine platforms against SARS-CoV-2 through the use of mRNA-1273, encoding" exact="viral" post="S protein [64â€&quot;66]. In May 2020, Moderna receivedÂ the"/>
 <result pre="similar approach involves administration of mRNA encoding an antibody protein." exact="Viral" post="proteins Subunit-based vaccines are a preferred option in terms"/>
 <result pre="induce immune responses producing neutralizing antibodies without risk of using" exact="infectious" post="viruses [68,69]. The genetic sequence of coronaviral S protein"/>
 <result pre="the native nature of virus structure in the presence or" exact="absence of" post="immunostimulatory TLR ligand sequence [80]. Subcutaneous delivery via microneedle"/>
 <result pre="immunity against the virus [48]. Antiviral agents against CoVs Understanding" exact="viral" post="replication and the molecules required for virus pathogenesis can"/>
 <result pre="drugs being clinically tested on CoVs. Nucleoside analogs, which inhibit" exact="viral" post="replication via interfering the cellular nucleotide synthesis, were tested"/>
 <result pre="interferons [9,96,97]. The protease inhibitors lopinavir and ritonavir, which inhibit" exact="viral" post="replication through binding to the viral proteases responsible for"/>
 <result pre="and ritonavir, which inhibit viral replication through binding to the" exact="viral" post="proteases responsible for proteolytic cleavage, have been tested against"/>
 <result pre="in accelerating development of promising clinically translatable therapeutics against different" exact="viral" post="infections [113]. Nanomedicine has already proven its activity against"/>
 <result pre="accelerating development of promising clinically translatable therapeutics against different viral" exact="infections" post="[113]. Nanomedicine has already proven its activity against several"/>
 <result pre="infections [113]. Nanomedicine has already proven its activity against several" exact="infectious diseases" post="including HBV [114], HIV-1 [115,116], respiratory syncytial virus [117]"/>
 <result pre="activity against several infectious diseases including HBV [114], HIV-1 [115,116]," exact="respiratory" post="syncytial virus [117] and influenza virus [118]. In addition,"/>
 <result pre="therapeutic or diagnostic agents, as well as immunogens against coronaviral" exact="infections" post="and most of these systems are illustrated in the"/>
 <result pre="MERS-CoV Induced RBD-specific immune responsesAntisera protected host cells from CoV" exact="infection" post="[127] Chaperna-based NPs Â MERS-CoV Induced mice immunization via"/>
 <result pre="enveloped virus [132] AuNPs S-AuNPs Spike protein of avian CoV" exact="Avian" post="CoV Significant improvement in vaccination potency [133] S-AuNPs Spike"/>
 <result pre="potency [133] S-AuNPs Spike protein SARS-CoV Induced strong IgG responsesLung" exact="eosinophilic" post="immunopathology [6] CoV: Coronavirus; MERS-CoV: Middle East respiratory syndrome"/>
 <result pre="IgG responsesLung eosinophilic immunopathology [6] CoV: Coronavirus; MERS-CoV: Middle East" exact="respiratory" post="syndrome coronavirus; NP: Nanoparticle; RBD: Receptor-binding domains; S-AuNP: Spike"/>
 <result pre="responsesLung eosinophilic immunopathology [6] CoV: Coronavirus; MERS-CoV: Middle East respiratory" exact="syndrome" post="coronavirus; NP: Nanoparticle; RBD: Receptor-binding domains; S-AuNP: Spike proteins-functionalized"/>
 <result pre="Nanoparticle; RBD: Receptor-binding domains; S-AuNP: Spike proteins-functionalized gold NP; SARS-CoV:" exact="Severe" post="acute respiratory syndrome coronavirus; VLP: Virus-like particle. Structure-based assembly"/>
 <result pre="RBD: Receptor-binding domains; S-AuNP: Spike proteins-functionalized gold NP; SARS-CoV: Severe" exact="acute" post="respiratory syndrome coronavirus; VLP: Virus-like particle. Structure-based assembly is"/>
 <result pre="Receptor-binding domains; S-AuNP: Spike proteins-functionalized gold NP; SARS-CoV: Severe acute" exact="respiratory" post="syndrome coronavirus; VLP: Virus-like particle. Structure-based assembly is the"/>
 <result pre="domains; S-AuNP: Spike proteins-functionalized gold NP; SARS-CoV: Severe acute respiratory" exact="syndrome" post="coronavirus; VLP: Virus-like particle. Structure-based assembly is the most"/>
 <result pre="which are structurally similar to virus particles, but without a" exact="viral" post="genome, are commonly used in vaccine development [124,125]. VLPs"/>
 <result pre="MERS-CoV entry. Instead of insect cell as an eukaryotic host," exact="bacterial" post="expression systems can be used in nanovaccine assembly processes"/>
 <result pre="(such as RBD of S protein) have been developed in" exact="bacterial" post="systems using ferritin as a molecular scaffold [128]. RBD"/>
 <result pre="a delivery system with chemical refolding to avoid aggregation during" exact="viral" post="antigens assembly [130,131]. Furthermore, self-assembled polypeptide NPs (25Â nm)"/>
 <result pre="of S proteins upon binding to AuNPs, resulting in lung" exact="eosinophilic" post="immunopathology [6,135]. Therefore, extensive study of S-AuNPs size and"/>
 <result pre="pathogenic coronaviruses. Â Platform Ligand Target Virus Notes Ref. MNP-based" exact="viral" post="RNA extraction pcMNPs Polycarboxyl groups Viral RNA SARS-CoV-2 One-step,"/>
 <result pre="Virus Notes Ref. MNP-based viral RNA extraction pcMNPs Polycarboxyl groups" exact="Viral" post="RNA SARS-CoV-2 One-step, simple, sensitiveExcellent paramagnetic propertyHigh purity and"/>
 <result pre="simple, sensitive [143] Self-assembled star-shaped CAuNPsâ€&quot;QD Virus-specific antibodies Target virus" exact="Avian" post="influenza A, adenovirus, CoVs Chiro-immunosensor with excitonâ€&quot;plasmon interaction in"/>
 <result pre="CoV: Coronavirus; E: Envelope; FITC: Fluorescein isothiocyanate; MERS-CoV: Middle East" exact="respiratory" post="syndrome coronavirus; MNP: Magnetic NP; N: Nucleocapsid; NP: Nanoparticle;"/>
 <result pre="Coronavirus; E: Envelope; FITC: Fluorescein isothiocyanate; MERS-CoV: Middle East respiratory" exact="syndrome" post="coronavirus; MNP: Magnetic NP; N: Nucleocapsid; NP: Nanoparticle; ORF:"/>
 <result pre="ORF: Open-reading frame; pcMNP: Polycarboxyl-functionalized MNP; QD: Quantum dot; SARS-CoV:" exact="Severe" post="acute respiratory syndrome coronavirus; SFNP: Silica-coated fluorescence NP; SMNP:"/>
 <result pre="Open-reading frame; pcMNP: Polycarboxyl-functionalized MNP; QD: Quantum dot; SARS-CoV: Severe" exact="acute" post="respiratory syndrome coronavirus; SFNP: Silica-coated fluorescence NP; SMNP: Superparamagnetic"/>
 <result pre="frame; pcMNP: Polycarboxyl-functionalized MNP; QD: Quantum dot; SARS-CoV: Severe acute" exact="respiratory" post="syndrome coronavirus; SFNP: Silica-coated fluorescence NP; SMNP: Superparamagnetic NP."/>
 <result pre="pcMNP: Polycarboxyl-functionalized MNP; QD: Quantum dot; SARS-CoV: Severe acute respiratory" exact="syndrome" post="coronavirus; SFNP: Silica-coated fluorescence NP; SMNP: Superparamagnetic NP. Accurate"/>
 <result pre="and isolation of nucleic acids from samples to avoid cross" exact="infection" post="or false-negative results. Magnetic NPs (MNPs) could play a"/>
 <result pre="MNPs functionalized with polycarboxyl groups (PC-coated NH2-MNPs) to specifically bind" exact="viral" post="RNA. With magnetic fields, nucleic acids are easily collected"/>
 <result pre="protects citrate ion-capped AuNPs from salt-induced aggregation. However, in the" exact="absence of" post="target genes, this protection does not exist, resulting in"/>
 <result pre="directly proportional to concentration of alkaline phosphatase and hence target" exact="viral" post="DNA [143]. Figure 3. Nanoparticle-based assays for coronaviruses. Chiral"/>
 <result pre="on the same chip, with each electrode attached to different" exact="viral" post="antigen [8]. Emerging diagnostic tests for SARS-CoV-2, such as"/>
 <result pre="colored line [147]. Figure 4. Emerging diagnostic tests for severe" exact="acute" post="respiratory syndrome coronavirus-2. C: Control well; G: Conjugate pad;"/>
 <result pre="line [147]. Figure 4. Emerging diagnostic tests for severe acute" exact="respiratory" post="syndrome coronavirus-2. C: Control well; G: Conjugate pad; S:"/>
 <result pre="[147]. Figure 4. Emerging diagnostic tests for severe acute respiratory" exact="syndrome" post="coronavirus-2. C: Control well; G: Conjugate pad; S: Sample"/>
 <result pre="al. [148] developed PEGylated gold nanorods loaded with peptide pregnancy-induced" exact="hypertension" post="(PIH), which has HR1 inhibition activity (IC50Â =Â 1.171Â"/>
 <result pre="subunit [148]. Figure 5. Nanoparticles-based therapy for coronaviruses via preventing" exact="viral" post="entry. NP: Nanoparticle; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2;"/>
 <result pre="therapy for coronaviruses via preventing viral entry. NP: Nanoparticle; SARS-CoV-2:" exact="Severe" post="acute respiratory syndrome coronavirus-2; RBD: Receptor-binding domain. Compared with"/>
 <result pre="for coronaviruses via preventing viral entry. NP: Nanoparticle; SARS-CoV-2: Severe" exact="acute" post="respiratory syndrome coronavirus-2; RBD: Receptor-binding domain. Compared with PIH"/>
 <result pre="coronaviruses via preventing viral entry. NP: Nanoparticle; SARS-CoV-2: Severe acute" exact="respiratory" post="syndrome coronavirus-2; RBD: Receptor-binding domain. Compared with PIH alone,"/>
 <result pre="via preventing viral entry. NP: Nanoparticle; SARS-CoV-2: Severe acute respiratory" exact="syndrome" post="coronavirus-2; RBD: Receptor-binding domain. Compared with PIH alone, PIH-gold"/>
 <result pre="[12]. Challenges &amp;amp; limitations Nanomedicine offers numerous opportunities against coronaviral" exact="infections" post="in the field of vaccination, molecular diagnosis and treatment."/>
 <result pre="and hurdles are encountered at different stages, starting from understanding" exact="viral" post="genomic and proteomic composition to clinical translation. While genomic"/>
 <result pre="reversion and pathogenesis is a critical safety issue such as" exact="eosinophilic" post="immunopathology in lungs and full-length S protein antigen-related liver"/>
 <result pre="S protein, are feasible and promising approaches to reduce the" exact="viral" post="burden. Moreover, numerous NP-based diagnostic systems have been reported"/>
 <result pre="To properly contain COVID-19 or any other emerging coronaviral pandemic," exact="complete" post="understanding of virus virulence and transmission are required. This"/>
 <result pre="CoV-related research. Executive summary Coronavirus In late 2019, novel severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in Wuhan/China, causing the"/>
 <result pre="research. Executive summary Coronavirus In late 2019, novel severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) emerged in Wuhan/China, causing the COVID-19Â"/>
 <result pre="Executive summary Coronavirus In late 2019, novel severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) emerged in Wuhan/China, causing the COVID-19Â disease"/>
 <result pre="respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in Wuhan/China, causing the COVID-19Â" exact="disease" post="and the WHO declared a pandemic. The seven Î±-"/>
 <result pre="These therapies target the different steps in CoVâ€™s lifecycle and" exact="viral" post="entry. Acknowledgments All the figures in this review (except"/>
 <result pre="COVID-19 outbreak a pandemic. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic 5.collab: World Health Organisation. Coronavirus" exact="disease" post="(COVID-19) situation report â€&quot; 168. http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200706-covid-19-sitrep-168.pdf?sfvrsn=7fed5c0b_2 6.SekimukaiH , Iwata-YoshikawaN"/>
 <result pre="S protein induces a strong antigen-specific IgG response against severe" exact="acute" post="respiratory syndrome-related coronavirus infection, but fails to induce protective"/>
 <result pre="protein induces a strong antigen-specific IgG response against severe acute" exact="respiratory" post="syndrome-related coronavirus infection, but fails to induce protective antibodies"/>
 <result pre="coronavirus infection, but fails to induce protective antibodies and limit" exact="eosinophilic" post="infiltration in lungs. Microbiol. Immunol.64(1), 33â€&quot;51 (2019).31692019 7.ColemanCM ,"/>
 <result pre="immunosensor for the corona virus associated with the Middle East" exact="respiratory" post="syndrome using an array of gold nanoparticle-modified carbon electrodes."/>
 <result pre="for the corona virus associated with the Middle East respiratory" exact="syndrome" post="using an array of gold nanoparticle-modified carbon electrodes. Microchimica"/>
 <result pre="status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus" exact="disease" post="2019 (COVID-19). J. Microbiol. Biotechnol.30(3), 313â€&quot;324 (2020).32238757 12.Å�oczechinA ,"/>
 <result pre="coronavirus. ACS Appl. Mater. Interfaces11(46), 42964â€&quot;42974 (2019).31633330 13.collab: Centers for" exact="Disease" post="Control and Prevention Public Health Image Library. Image 23354."/>
 <result pre=", HongZSet al.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak â€&quot; an update on the status."/>
 <result pre=", ZhaoS , YuBet al.A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature579(7798), 265â€&quot;269 (2020).32015508 16.KhailanyRA , SafdarM"/>
 <result pre="ZhaoS , YuBet al.A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature579(7798), 265â€&quot;269 (2020).32015508 16.KhailanyRA , SafdarM ,"/>
 <result pre="(2015). 18.BÃ¡rcenaM , OostergetelGT , BartelinkWet al.Cryo-electron tomography of mouse" exact="hepatitis" post="virus: insights into the structure of the coronavirion. Proc."/>
 <result pre="(2009).19124777 19.NeumanBW , AdairBD , YoshiokaCet al.Supramolecular architecture of severe" exact="acute" post="respiratory syndrome coronavirus revealed by electron cryomicroscopy. J. Virol.80(16),"/>
 <result pre="19.NeumanBW , AdairBD , YoshiokaCet al.Supramolecular architecture of severe acute" exact="respiratory" post="syndrome coronavirus revealed by electron cryomicroscopy. J. Virol.80(16), 7918â€&quot;7928"/>
 <result pre=", AdairBD , YoshiokaCet al.Supramolecular architecture of severe acute respiratory" exact="syndrome" post="coronavirus revealed by electron cryomicroscopy. J. Virol.80(16), 7918â€&quot;7928 (2006).16873249"/>
 <result pre="(2006).16873249 20.SuiJ , LiW , MurakamiAet al.Potent neutralization of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus by a human mAb to"/>
 <result pre="20.SuiJ , LiW , MurakamiAet al.Potent neutralization of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus by a human mAb to S1"/>
 <result pre=", LiW , MurakamiAet al.Potent neutralization of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus by a human mAb to S1 protein"/>
 <result pre="coronavirus. Nature426(6965), 450â€&quot;454 (2003).14647384 23.ZhouP , YangX-L , WangX-Get al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="coronaviruses. https://statnano.com/news/67513/An-Overview-of-Nanotechnology-Patents-Focusing-on-Coronaviruses 26.UdugamaB , KadhiresanP , KozlowskiHNet al.Diagnosing COVID-19: the" exact="disease" post="and tools for detection. ACS Nano14(4), 3822â€&quot;3835 (2020).32223179 27.LiW"/>
 <result pre="coronaviruses. Science310(5748), 676â€&quot;679 (2005).16195424 28.LauSKP , WooPCY , LiKSMet al.Severe" exact="acute" post="respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc."/>
 <result pre="Science310(5748), 676â€&quot;679 (2005).16195424 28.LauSKP , WooPCY , LiKSMet al.Severe acute" exact="respiratory" post="syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl"/>
 <result pre="676â€&quot;679 (2005).16195424 28.LauSKP , WooPCY , LiKSMet al.Severe acute respiratory" exact="syndrome" post="coronavirus-like virus in Chinese horseshoe bats. Proc. Natl Acad."/>
 <result pre="ItheteNL , RichardsLRet al.Rooting the phylogenetic tree of Middle East" exact="respiratory" post="syndrome coronavirus by characterization of a conspecific virus from"/>
 <result pre=", RichardsLRet al.Rooting the phylogenetic tree of Middle East respiratory" exact="syndrome" post="coronavirus by characterization of a conspecific virus from an"/>
 <result pre="syndrome coronavirus by characterization of a conspecific virus from an" exact="African" post="bat. J. Virol.88(19), 11297â€&quot;11303 (2014).25031349 31.van BoheemenS , de"/>
 <result pre="LauberCet al.Genomic characterization of a newly discovered coronavirus associated with" exact="acute" post="respiratory distress syndrome in humans. mBio3(6), e00473â€&quot;00412 (2012).23170002 32.ZakiAM"/>
 <result pre="al.Genomic characterization of a newly discovered coronavirus associated with acute" exact="respiratory" post="distress syndrome in humans. mBio3(6), e00473â€&quot;00412 (2012).23170002 32.ZakiAM ,"/>
 <result pre="of a newly discovered coronavirus associated with acute respiratory distress" exact="syndrome" post="in humans. mBio3(6), e00473â€&quot;00412 (2012).23170002 32.ZakiAM , van BoheemenS"/>
 <result pre=", FouchierRAMIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia. N. Engl. J. Med.367(19), 1814â€&quot;1820 (2012).23075143"/>
 <result pre=", HongZ-Set al.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak â€&quot; an update on the status."/>
 <result pre="Med. Res.7(1), 1â€&quot;10 (2020).31928528 35.ZhouP , YangXL , WangXGet al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="Immunity52(4), 583â€&quot;589 (2020).32259480 37.AiT , YangZ , HouHet al.Correlation of" exact="chest" post="CT and RT-PCR testing in coronavirus disease 2019 (COVID-19)"/>
 <result pre="HouHet al.Correlation of chest CT and RT-PCR testing in coronavirus" exact="disease" post="2019 (COVID-19) in China: a report of 1014 cases."/>
 <result pre="(2020).32234451 41.LiuJ , LiaoX , QianSet al.Community transmission of severe" exact="acute" post="respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg. Infect."/>
 <result pre="41.LiuJ , LiaoX , QianSet al.Community transmission of severe acute" exact="respiratory" post="syndrome coronavirus 2, Shenzhen, China, 2020. Emerg. Infect. Dis.26(6),"/>
 <result pre=", LiaoX , QianSet al.Community transmission of severe acute respiratory" exact="syndrome" post="coronavirus 2, Shenzhen, China, 2020. Emerg. Infect. Dis.26(6), 1320â€&quot;1323"/>
 <result pre="Infect. Dis.26(6), 1320â€&quot;1323 (2020).32125269 42.ChanJFW , YuanS , KokKHet al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="(2020).32125269 42.ChanJFW , YuanS , KokKHet al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="a stool specimen of a laboratory-confirmed case of the coronavirus" exact="disease" post="2019 (COVID-19). CCDC Weekly2(8), 123â€&quot;124 (2020). 44.XiaoF , TangM"/>
 <result pre=", ZhengX , LiuY , LiX , ShanHEvidence for gastrointestinal" exact="infection" post="of SARS-CoV-2. Gastroenterology158(6), 1831â€&quot;1833 (2020).32142773 45.HolmesKV , EnjuanesLThe SARS"/>
 <result pre="characterization of DNA vaccines targeting the nucleocapsid protein of severe" exact="acute" post="respiratory syndrome coronavirus. J. Virol.78(9), 4638â€&quot;4645 (2004).15078946 54.DonnellyJJ ,"/>
 <result pre="of DNA vaccines targeting the nucleocapsid protein of severe acute" exact="respiratory" post="syndrome coronavirus. J. Virol.78(9), 4638â€&quot;4645 (2004).15078946 54.DonnellyJJ , UlmerJB"/>
 <result pre="DNA vaccines targeting the nucleocapsid protein of severe acute respiratory" exact="syndrome" post="coronavirus. J. Virol.78(9), 4638â€&quot;4645 (2004).15078946 54.DonnellyJJ , UlmerJB ,"/>
 <result pre="Rev. Immunol.15(1), 617â€&quot;648 (1997).9143702 55.SinJI , WeinerDBImproving DNA vaccines targeting" exact="viral infection." post="Intervirology43(4â€&quot;6), 233â€&quot;246 (2000).11251379 56.WangSF , TsengSP , YenCHet al.Antibody-dependent"/>
 <result pre="233â€&quot;246 (2000).11251379 56.WangSF , TsengSP , YenCHet al.Antibody-dependent SARS coronavirus" exact="infection" post="is mediated by antibodies against spike proteins. Biochem. Biophys."/>
 <result pre="entry. J. Virol.94(5), e02015â€&quot;02019 (2020).31826992 58.TiradoSMC , YoonK-JAntibody-dependent enhancement of" exact="virus infection" post="and disease. Viral Immunol.16(1), 69â€&quot;86 (2003).12725690 59.SeoSH , WangL"/>
 <result pre="J. Virol.94(5), e02015â€&quot;02019 (2020).31826992 58.TiradoSMC , YoonK-JAntibody-dependent enhancement of virus" exact="infection" post="and disease. Viral Immunol.16(1), 69â€&quot;86 (2003).12725690 59.SeoSH , WangL"/>
 <result pre="(2020).31826992 58.TiradoSMC , YoonK-JAntibody-dependent enhancement of virus infection and disease." exact="Viral" post="Immunol.16(1), 69â€&quot;86 (2003).12725690 59.SeoSH , WangL , SmithR ,"/>
 <result pre=", WangL , SmithR , CollissonEWThe carboxyl-terminal 120-residue polypeptide of" exact="infectious" post="bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects"/>
 <result pre="WangL , SmithR , CollissonEWThe carboxyl-terminal 120-residue polypeptide of infectious" exact="bronchitis" post="virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens"/>
 <result pre="virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from" exact="acute" post="infection. J. Virol.71(10), 7889â€&quot;7894 (1997).9311878 60.collab: Inovio. Inovio accelerates"/>
 <result pre="Rev. Microbiol.11, 836â€&quot;848 (2013).24217413 69.OkbaNMA , RajVS , HaagmansBLMiddle East" exact="respiratory" post="syndrome coronavirus vaccines: current status and novel approaches. Curr."/>
 <result pre="Microbiol.11, 836â€&quot;848 (2013).24217413 69.OkbaNMA , RajVS , HaagmansBLMiddle East respiratory" exact="syndrome" post="coronavirus vaccines: current status and novel approaches. Curr. Opin."/>
 <result pre=", SaijoM , FukushiSInability of rat DPP4 to allow MERS-CoV" exact="infection" post="revealed by using a VSV pseudotype bearing truncated MERS-CoV"/>
 <result pre="WangL , van DoremalenNet al.Efficacy of an adjuvanted Middle East" exact="respiratory" post="syndrome coronavirus spike protein vaccine in dromedary camels and"/>
 <result pre=", van DoremalenNet al.Efficacy of an adjuvanted Middle East respiratory" exact="syndrome" post="coronavirus spike protein vaccine in dromedary camels and alpacas."/>
 <result pre=", YaoY , DengYet al.Recombinant receptor binding domain protein induces" exact="partial" post="protective immunity in Rhesus macaques against Middle East respiratory"/>
 <result pre="induces partial protective immunity in Rhesus macaques against Middle East" exact="respiratory" post="syndrome coronavirus challenge. EBioMedicine2(10), 1438â€&quot;1446 (2015).26629538 76.ChenY , LuS"/>
 <result pre="partial protective immunity in Rhesus macaques against Middle East respiratory" exact="syndrome" post="coronavirus challenge. EBioMedicine2(10), 1438â€&quot;1446 (2015).26629538 76.ChenY , LuS ,"/>
 <result pre="of spike proteins is a potential vaccine against Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) infection. Vaccine35(1), 10â€&quot;18 (2017).27899228 78.DuL ,"/>
 <result pre="spike proteins is a potential vaccine against Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) infection. Vaccine35(1), 10â€&quot;18 (2017).27899228 78.DuL , HeY"/>
 <result pre="BukreyevA , YangLet al.Contributions of the structural proteins of severe" exact="acute" post="respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad."/>
 <result pre=", YangLet al.Contributions of the structural proteins of severe acute" exact="respiratory" post="syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci."/>
 <result pre="YangLet al.Contributions of the structural proteins of severe acute respiratory" exact="syndrome" post="coronavirus to protective immunity. Proc. Natl Acad. Sci. USA101(26),"/>
 <result pre="87.LiuJ , SunY , QiJet al.The membrane protein of severe" exact="acute" post="respiratory syndrome coronavirus acts as a dominant immunogen revealed"/>
 <result pre=", SunY , QiJet al.The membrane protein of severe acute" exact="respiratory" post="syndrome coronavirus acts as a dominant immunogen revealed by"/>
 <result pre="SunY , QiJet al.The membrane protein of severe acute respiratory" exact="syndrome" post="coronavirus acts as a dominant immunogen revealed by a"/>
 <result pre="Infect. Dis.202(8), 1171â€&quot;1180 (2010).20831383 88.HofmannH , HattermannK , MarziAet al.S" exact="Protein" post="of severe acute respiratory syndrome-associated coronavirus mediates entry into"/>
 <result pre="(2010).20831383 88.HofmannH , HattermannK , MarziAet al.S Protein of severe" exact="acute" post="respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines"/>
 <result pre="88.HofmannH , HattermannK , MarziAet al.S Protein of severe acute" exact="respiratory" post="syndrome-associated coronavirus mediates entry into hepatoma cell lines and"/>
 <result pre="(2004).15163706 89.SuiJ , LiW , MurakamiAet al.Potent neutralization of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus by a human mAb to"/>
 <result pre="89.SuiJ , LiW , MurakamiAet al.Potent neutralization of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus by a human mAb to S1"/>
 <result pre=", LiW , MurakamiAet al.Potent neutralization of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus by a human mAb to S1 protein"/>
 <result pre="in an attenuated SARS-CoV for the design of a genetically" exact="stable" post="vaccine. PLoS Pathog.11(10), e1005215 (2015).26513244 91.HolshueML , DeboltC ,"/>
 <result pre="and interferon therapy in patients infected with the Middle East" exact="respiratory" post="syndrome coronavirus: an observational study. Int. J. Infect. Dis20,"/>
 <result pre="interferon therapy in patients infected with the Middle East respiratory" exact="syndrome" post="coronavirus: an observational study. Int. J. Infect. Dis20, 42â€&quot;46"/>
 <result pre="(2014).24406736 98.WuCY , JanJT , MaSHet al.Small molecules targeting severe" exact="acute" post="respiratory syndrome human coronavirus. Proc. Natl Acad. Sci. USA101(27),"/>
 <result pre="98.WuCY , JanJT , MaSHet al.Small molecules targeting severe acute" exact="respiratory" post="syndrome human coronavirus. Proc. Natl Acad. Sci. USA101(27), 10012"/>
 <result pre=", JanJT , MaSHet al.Small molecules targeting severe acute respiratory" exact="syndrome" post="human coronavirus. Proc. Natl Acad. Sci. USA101(27), 10012 (2004).15226499"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. Biosci. Trend.14(1), 72â€&quot;73 (2020). 103.ColsonP ,"/>
 <result pre=", SunYet al.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal model. Cell"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal model. Cell Res.23(2), 300â€&quot;302 (2013).23208422 106.VincentMJ"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Res.23(2), 300â€&quot;302 (2013).23208422 106.VincentMJ"/>
 <result pre=", BenjannetSet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol. J.2(1), 69 (2005).16115318 107.RolainJM , ColsonP"/>
 <result pre="chloroquine and its hydroxyl analogue to face bacterial, fungal and" exact="viral" post="infections in the 21st century. Int. J. Antimicrob. Agents30(4),"/>
 <result pre="and its hydroxyl analogue to face bacterial, fungal and viral" exact="infections" post="in the 21st century. Int. J. Antimicrob. Agents30(4), 297â€&quot;308"/>
 <result pre=", JohnJ , HettaHFNanomedicine as a future therapeutic approach for" exact="Hepatitis" post="C virus. Nanomedicine (Lond.)14(11), 1471â€&quot;1491 (2019).31166139 114.LuL , SunRW"/>
 <result pre="114.LuL , SunRW , ChenR , HuiCKet al.Silver nanoparticles inhibit" exact="hepatitis" post="B virus replication. Antiviral Ther.13(2), 253â€&quot;262 (2008). 115.SunRWY ,"/>
 <result pre=", VigK , PillaiSR , SinghSRSilver nanoparticles inhibit replication of" exact="respiratory" post="syncytial virus. J. Biomed. Nanotechnol.4(2), 149â€&quot;158 (2008). 118.PappI ,"/>
 <result pre="149â€&quot;158 (2008). 118.PappI , SiebenC , LudwigKet al.Inhibition of influenza" exact="virus infection" post="by multivalent sialic-acid-functionalized gold nanoparticles. Small6(24), 2900â€&quot;2906 (2010).21104827 119.AbdEllah"/>
 <result pre="(2008). 118.PappI , SiebenC , LudwigKet al.Inhibition of influenza virus" exact="infection" post="by multivalent sialic-acid-functionalized gold nanoparticles. Small6(24), 2900â€&quot;2906 (2010).21104827 119.AbdEllah"/>
 <result pre="(2010).21104827 119.AbdEllah NH , AbouelmagdSASurface functionalization of polymeric nanoparticles for" exact="tumor" post="drug delivery: approaches and challenges. Exp. Opin. Drug Deliv.14(2),"/>
 <result pre="Vaccine32(3), 327â€&quot;337 (2014).24295808 122.PatiR , ShevtsovM , SonawaneANanoparticle vaccines against" exact="infectious diseases." post="Front. Immunol.9(2224), 2224 (2018).30337923 123.MubarakA , AlturaikiW , HemidaMGMiddle"/>
 <result pre="Front. Immunol.9(2224), 2224 (2018).30337923 123.MubarakA , AlturaikiW , HemidaMGMiddle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development."/>
 <result pre="Immunol.9(2224), 2224 (2018).30337923 123.MubarakA , AlturaikiW , HemidaMGMiddle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J."/>
 <result pre="particle mimetic nanovesicles displaying the S protein of Middle East" exact="respiratory" post="syndrome coronavirus using insect cells. J. Biotechnol.306, 177â€&quot;184 (2019).31614169"/>
 <result pre="mimetic nanovesicles displaying the S protein of Middle East respiratory" exact="syndrome" post="coronavirus using insect cells. J. Biotechnol.306, 177â€&quot;184 (2019).31614169 127.WangC"/>
 <result pre=", SonA , KimJet al.Chaperna-mediated assembly of ferritin-based Middle East" exact="respiratory" post="syndrome-coronavirus nanoparticles. Front. Immunol.9(1093), 1â€&quot;20 (2018).29403488 129.FangN , FrazerIH"/>
 <result pre="capsid protein expressed from a baculovirus system compared with a" exact="vaccinia" post="virus system. Biotechnol. Appl. Biochem.32(1), 27â€&quot;33 (2000).10918035 130.ToddTJ ,"/>
 <result pre="as novel immunogens: design and analysis of a prototypic severe" exact="acute" post="respiratory syndrome vaccine. Chem. Biol. Drug Des.73(1), 53â€&quot;61 (2009).19152635"/>
 <result pre="novel immunogens: design and analysis of a prototypic severe acute" exact="respiratory" post="syndrome vaccine. Chem. Biol. Drug Des.73(1), 53â€&quot;61 (2009).19152635 133.ChenHW"/>
 <result pre="immunogens: design and analysis of a prototypic severe acute respiratory" exact="syndrome" post="vaccine. Chem. Biol. Drug Des.73(1), 53â€&quot;61 (2009).19152635 133.ChenHW ,"/>
 <result pre="SongW , RuX , ZhouW , YuXA simple magnetic nanoparticles-based" exact="viral" post="RNA extraction method for efficient detection of SARS-CoV-2. bioRxiv"/>
 <result pre="for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of" exact="pneumonia" post="(COVID-19). medRxiv (2020) (Preprint). 147.HuangP , WangH , CaoZet"/>
 <result pre="XuYet al.Novel gold nanorod-based HR1 peptide inhibitor for Middle East" exact="respiratory" post="syndrome coronavirus. ACS Appl. Mater. Interfaces11(22), 19799â€&quot;19807 (2019).31099550 149.HanY"/>
 <result pre="al.Novel gold nanorod-based HR1 peptide inhibitor for Middle East respiratory" exact="syndrome" post="coronavirus. ACS Appl. Mater. Interfaces11(22), 19799â€&quot;19807 (2019).31099550 149.HanY ,"/>
</results>
